TAMOXIFEN IN THE TREATMENT OF MALE BREAST-CARCINOMA
TAMOXIFEN IN THE TREATMENT OF MALE BREAST-CARCINOMA
复制标题
DOI：
10.1016/s0009-9260(83)80408-5
复制
发表时间：
1983-01-01
影响因子：
2.6
通讯作者：
RIBEIRO, GG
中科院分区：
文献类型：
--
作者：
RIBEIRO, GG
患有晚期男性乳腺癌的患者[24]接受柠檬酸他莫昔芬（Nolvadex）治疗。客观回归率为 37.5%，其中 5 例完全缓解，4 例部分缓解。两名患者的病情稳定了 24 个月。每个。软组织疾病、骨转移和肺转移出现疾病消退。反应持续时间为8-60个月。平均为 21 个月。鉴于其独特的副作用缺乏以及患者的年龄组（平均年龄 63 岁），他莫昔芬应成为睾丸切除术或肾上腺切除术之前的第一线内分泌治疗。
Patients [24] with advanced carcinoma of the male breast were treated with tamoxifen citrate (Nolvadex). An objective regression rate of 37.5% was obtained, with 5 complete and 4 partial responses. Two patients had stabilization of their disease for 24 mo. each. Regression of disease was noted in soft-tissue disease, bone and lung metastases. The duration of response ranged from 8-60 mo. with a mean of 21 mo. In view of the singular lack of side-effects and the age group of the patients (mean age 63 yr), tamoxifen should be the 1st line of endocrine therapy before orchidectomy or adrenalectomy.